drugset / Trial / NCT02249351

Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type

NCT02249351

Phase 2 Terminated 54 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess symptomatic efficacy, safety and tolerability of talsaclidine in patients with mild to moderate dementia of Alzheimer type

Timeline

Start
1999-12
Primary completion
2000-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Talsaclidine Small molecule 48 mg Oral
Subject Talsaclidine Small molecule 60 mg Oral

Indications